Supporting research to find new targets for non-invasive brain stimulation and understand the neurobiological and behavioral responses that precede clinical outcomes in substance use disorder treatment.
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: August 14, 2025 (Renewal/Resubmission/Revision) | January 16, 2026 (New & Renewal/Resubmission/Revision) | August 14, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: ~$1.5M/year for up to 6 awards across related NOFOs; no budget cap, but budgets must reflect actual project needs; max project period: 5 years.
Summary: Supports basic experimental studies in humans to identify and validate novel non-invasive brain stimulation targets and SUD-relevant neurobiological, cognitive, and behavioral responses that precede clinical outcomes.
Key Information: Applications must propose basic experimental studies with humans (BESH) that meet both the NIH clinical trial and basic research definitions; annual milestones are required.
This opportunity from the National Institute on Drug Abuse (NIDA) at NIH supports clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to characterize substance use disorder (SUD)-relevant neurobiological, cognitive, and behavioral responses to NIBS that may precede clinical outcomes such as reduced craving or substance use. The focus is on basic experimental studies in humans (BESH) that prospectively assign participants to interventions to understand fundamental mechanisms, not to test specific clinical applications.
The goal is to advance mechanistic understanding of how neuromodulation affects brain circuits and behavior relevant to SUD, ultimately informing future clinical trial design and the development of new treatment targets and proximal efficacy metrics.